Get the Stockscreener App
67.60
0.82%
-0.56
After Hours:
67.60
Soleno Therapeutics Inc stock is traded at $67.60, with a volume of 1.40M.
It is down -0.82% in the last 24 hours and down -0.10% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
See More
Previous Close:
$68.16
Open:
$68.46
24h Volume:
1.40M
Relative Volume:
0.78
Market Cap:
$3.59B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-22.56
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
+18.91%
1M Performance:
-0.10%
6M Performance:
-5.39%
1Y Performance:
+33.89%
1-Day Range:
$65.97
$68.46
1-Week Range:
$61.00
$68.46
52-Week Range:
$41.50
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
67.60 | 3.62B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-23-25 | Initiated | TD Cowen | Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
How to escape a deep drawdown in Soleno Therapeutics Inc.Weekly Market Report & AI Powered Buy and Sell Recommendations - newser.com
Wells Fargo Reiterates a Buy Rating on Soleno Therapeutics (SLNO), Sets a PT of $123 - Insider Monkey
What Wall Street predicts for Soleno Therapeutics Inc. stock priceRecession Risk & AI Forecast Swing Trade Picks - newser.com
Can Soleno Therapeutics Inc. stock deliver sustainable ROEEarnings Summary Report & Capital Efficient Trading Techniques - newser.com
Detecting support and resistance levels for Soleno Therapeutics Inc.2025 Trading Volume Trends & Daily Growth Stock Tips - newser.com
How Soleno Therapeutics Inc. (6XC) stock stacks up against competitors2025 Market Outlook & Smart Money Movement Tracker - newser.com
Is Soleno Therapeutics Inc. stock supported by strong cash flows2025 Volatility Report & Fast Exit and Entry Trade Guides - newser.com
How Soleno Therapeutics Inc. stock performs in rate cut cycles2025 Support & Resistance & Momentum Based Trading Signals - newser.com
Momentum divergence signals in Soleno Therapeutics Inc. chartMarket Activity Recap & Safe Entry Trade Reports - newser.com
Will Soleno Therapeutics Inc. (6XC) stock justify high valuationOptions Play & Step-by-Step Trade Execution Guides - newser.com
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Exploring an 82.77% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc.SLNO - WV News
Soleno Therapeutics Insiders Sold US$23m Of Shares Suggesting Hesitancy - 富途牛牛
SLNO Investor News: If You Have Suffered Losses in Soleno - GlobeNewswire
What analysts say about Soleno Therapeutics Inc stockTrading Volume Surges & Explore Stocks for Free with Our Research Portal - Early Times
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Baird reiterates Outperform rating on Soleno Therapeutics stock after rival’s trial failure - Investing.com Canada
Baird reiterates Outperform rating on Soleno Therapeutics stock after rival’s trial failure By Investing.com - Investing.com South Africa
SOLENO INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman - GlobeNewswire
Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman - GlobeNewswire Inc.
Wells Fargo Sticks to Their Buy Rating for Soleno Therapeutics (SLNO) - The Globe and Mail
Soleno Therapeutics (SLNO) Jumps 13.46% as Competitor Fails Prader-Willi Treatment Trial - MSN
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):